Price Crosses Moving Average
|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||69.42 - 72.94|
|52 Week Range||21.06 - 79.65|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.10|
Subscribe to Yahoo Finance Plus to view Fair Value for PRTALearn more
DUBLIN, June 02, 2023--Prothena today announced that it will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 1:00 PM ET.
DUBLIN, May 16, 2023--Prothena announced today the appointment of Dr. Billy Dunn, the founding Director of the Office of Neuroscience, CDER, to its Board of Directors.
One thing we could say about the analysts on Prothena Corporation plc ( NASDAQ:PRTA ) - they aren't optimistic, having...
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, May 04, 2023--Prothena today reported financial results for the first quarter of 2023 and provided business highlights.
DUBLIN, April 27, 2023--Prothena today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023.
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, April 24, 2023--Prothena today announced that members of its management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.
DEERFIELD, Ill. & DUBLIN, April 13, 2023--Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. As part of the collaboration, Walgreens will leverage its national footprint, portfolio of industry-leading healthca
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
DUBLIN, March 31, 2023--Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
DUBLIN, Ireland, March 21, 2023--Prothena announced today that members of its senior management team will participate in a fireside chat at Stifel 2023 Virtual CNS Days on March 28 .
DUBLIN, March 14, 2023--Prothena announced broad participation at AD/PD 2023 highlighting leadership in advancing treatments for Alzheimer’s and Parkinson’s disease
Market forces rained on the parade of Prothena Corporation plc ( NASDAQ:PRTA ) shareholders today, when the analysts...
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
DUBLIN, February 23, 2023--Prothena Corporation plc today reported financial results for the 4th quarter and full year 2022.
DUBLIN, February 16, 2023--Prothena Corporation plc announced that it will report its fourth quarter and full year 2022 financial results on February 23, 2023.
All investors are after gains, but in trying to find the right stocks to increase a portfolio’s value, are constantly inundated with massive amounts of data. Thus, separating the wheat from the chaff is an arduous process but there are tools to help make sense of it all. TipRanks’ Smart Score is one. The tool collects all the info needed on any given stock and sorts it out into 8 different categories, all known to impact future performance. Combining those factors, they are then distilled into a
DUBLIN, February 03, 2023--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prothena Corporation plc (NASDAQ: PRTA) announced topline data from the Phase 1 single ascending dose (SAD) study for PRX005 for Alzheimer's disease. PRX005 is one of three global neuroscience research and development programs in collaboration between Prothena and Bristol Myers Squibb & Co (NYSE: BMY). Study participants received a single dose of PRX0005 or placebo intravenously (IV) and were followed for up to two months. The data exhibited that all three dose-level cohorts of PRX005 were gener
DUBLIN, January 31, 2023--Prothena announced positive topline Phase 1 SAD study results for PRX005, an investigational tau antibody for the treatment of Alzheimer’s disease.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...